Catalyst Pharmaceuticals Inc (STU:CN2)
€ 20.71 0.15 (0.73%) Market Cap: 2.46 Bil Enterprise Value: 2.04 Bil PE Ratio: 18.19 PB Ratio: 3.87 GF Score: 88/100

Q3 2019 Catalyst Pharmaceuticals Inc Earnings Call Transcript

Nov 13, 2019 / 01:30PM GMT
Release Date Price: €3.94 (-10.45%)
Operator

Greetings. Welcome to the Catalyst Pharmaceuticals CPRX Third Quarter 2019 Results Conference Call. (Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to your host, Ali Grande, Chief Financial Officer. Please go ahead.

Alicia Grande
Catalyst Pharmaceuticals, Inc. - VP, Treasurer & CFO

Good morning, everyone, and thanks for joining today's conference call. Joining me on today's call are members of the Catalyst management team, including Pat McEnany, Chairman and Chief Executive Officer; Dr. Steven Miller, Chief Operating Officer and Chief Scientific Officer; and Dan Brennan, our Chief Commercial Officer.

Before we begin, I would like to remind you that in the following comments and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of the federal securities laws. These statements relate to our current expectations, estimates and projections and are not guarantees of future performance. They involve risks,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot